Clinical Trials Logo

Clinical Trial Summary

To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.


Clinical Trial Description

Primary Objectives: --The primary objective is to determine the safety and identify the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of JV-213 in patients with r/r B-cell lymphomas. Hypothesis: JV-213 will be safe, well-tolerated, and effective in patients with r/r B-cell lymphomas. Secondary Objectives: --The secondary objective is to determine the efficacy in adults with r/r LBCL and FL grade 3B treated at the MTD or RP2D of JV-213. Although the clinical benefit of JV-213 has not yet been established, the intent of offering this treatment is to provide a possible therapeutic benefit, and thus the patient will be carefully monitored for tumor response and symptom relief in addition to safety and tolerability. Secondary endpoints include overall response rate (ORR; including CR + PR) and CR rate as defined by the Lugano Classification response criteria for malignant lymphoma,53 DOR, PFS, and OS. Hypothesis: JV-213 will induce an ORR of at least 40% in adult subjects with r/r B-cell lymphomas. Exploratory Objectives: --The exploratory objectives are to assess the cellular kinetics and pharmacodynamic effects of JV-213 anti-CD79b CAR T-cell product and to evaluate biomarkers associated with response, resistance, and toxicity after administration of JV-213 in blood and tumor samples. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05773040
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Active, not recruiting
Phase Phase 1
Start date April 14, 2023
Completion date December 31, 2027

See also
  Status Clinical Trial Phase
Completed NCT01359982 - Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects Phase 1
Completed NCT02140736 - Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
Completed NCT00947739 - Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma Phase 1
Completed NCT00725634 - A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma Phase 1
Completed NCT00222443 - Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy Phase 1
Recruiting NCT02211755 - Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors Phase 1
Completed NCT02048488 - A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Recruiting NCT06148220 - A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors N/A
Completed NCT01031641 - Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing
Withdrawn NCT02786485 - Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT Phase 1
Completed NCT01387841 - Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting Phase 2
Completed NCT00396864 - Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma Phase 1
Terminated NCT00023166 - Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas Phase 1
Recruiting NCT04417803 - Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques N/A
Recruiting NCT05775406 - Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors Phase 1
Recruiting NCT02274584 - CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) Phase 1/Phase 2
Recruiting NCT01836822 - Bronchoscopic Sampling Techniques in Sarcoidosis N/A
Completed NCT02902237 - tTF-NGR Phase I Study Phase 1
Completed NCT02578316 - A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies. Phase 1
Recruiting NCT00900198 - Collection of Tissue Samples for Cancer Research